Several point mutations in the structural domain of NPM–ALK kinase have been identified in ALK+ ALCL (L1122V, L1196M, F1174V, L1198F, P1139S, and G1202R) that have been implicated in the development of resistance to ALK TKIs (55). The gene discussed is ALK; the disease is anaplastic large cell lymphoma.